Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:36:37时区推断·⟳ 抓取 19:37:35·⚡ 决策 07-22 19:44:10 +6m35s·97.0 天前
FDA 受理 BridgeBio encaleret NDA，PDUFA 日期为 2027 年 5 月 8 日
FDA 受理 NDA 且暂不计划召开咨询委员会，对 encaleret 的监管路径是正面进展。
📄 原文Investing.com↗ 原文
FDA accepts BridgeBio’s drug application for rare genetic disorder
+61% upside, this growing AI-picked healthcare leader is trading at 52-week lows PALO ALTO, Calif. - BridgeBio Pharma,…
不做 BridgeBio Pharma（BBIO.US）
NDA 受理是正面但不是批准，PDUFA 远至 2027-05-08，且相对 161.5 亿美元市值缺少可量化短线增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- BridgeBio 称 FDA 已受理 encaleret NDA，PDUFA 为 2027-05-08，当前不计划召开 AdCom。市场反应:BBIO.US 最新价 82.45 美元，较前收涨 2.09%，近 20 日涨 19.63%。
关键理由
- FDA 受理 NDA 且暂不计划召开咨询委员会，对 encaleret 的监管路径是正面进展。
- ADH1 在美国自 2023 年 10 月以来确诊人数超过 2100 人，但 PDUFA 在 2027 年 5 月 8 日，商业化现金流仍远。
- BBIO.US 市值约 161.5 亿美元，单一罕见病 NDA 受理相对市值弹性有限，且近 20 日已涨 19.63%。
主要风险
- NDA 受理不是批准，仍有审评和标签风险；未披露定价、渗透率和销售峰值，难以给出短线市值级增量。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
内部 KB 未命中 encaleret 相关可靠商业化量级，无法验证短线收入弹性。
检索:BridgeBio encaleret ADH1 market size revenue PDUFA May 8 2027
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,001 字
+61% upside, this growing AI-picked healthcare leader is trading at 52-week lows
PALO ALTO, Calif. - BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced today that the U.S. Food and Drug Administration has accepted its New Drug Application for encaleret, a treatment for autosomal dominant hypocalcemia type 1.
The FDA assigned a Prescription Drug User Fee Act target action date of May 8, 2027, according to a press release statement. The agency indicated it does not currently plan to hold an advisory committee meeting to discuss the application.
ADH1 is a form of genetic hypoparathyroidism caused by variants in the calcium-sensing receptor gene. The condition affects calcium regulation in the body and can result in symptoms including muscle cramps, seizures, and kidney complications. As of April 2026, over 2,100 individuals have been diagnosed with ADH1 in the U.S. since October 2023, based on claims data.
The application is supported by results from CALIBRATE, a Phase 3 clinical trial in which encaleret met all pre-specified primary and key secondary efficacy endpoints. Results were presented at the European Congress of Endocrinology 2026 and the Endocrine Society 2026 annual meeting.
Encaleret is an orally administered small molecule designed to modulate the calcium sensing receptor. The drug has received Fast Track Designation from the FDA and Orphan Drug Designation in the U.S., European Union, and Japan.
BridgeBio stated it intends to submit a Marketing Authorization Application to the European Medicines Agency for encaleret in ADH1 in the second half of 2026.
The company is currently enrolling CALIBRATE-PEDS, a Phase 2/3 trial studying encaleret in pediatric ADH1. BridgeBio also plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism, later this summer.
There are currently no approved therapies specifically indicated for ADH1.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PALO ALTO, Calif. - BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced today that the U.S. Food and Drug Administration has accepted its New Drug Application for encaleret, a treatment for autosomal dominant hypocalcemia type 1.
The FDA assigned a Prescription Drug User Fee Act target action date of May 8, 2027, according to a press release statement. The agency indicated it does not currently plan to hold an advisory committee meeting to discuss the application.
ADH1 is a form of genetic hypoparathyroidism caused by variants in the calcium-sensing receptor gene. The condition affects calcium regulation in the body and can result in symptoms including muscle cramps, seizures, and kidney complications. As of April 2026, over 2,100 individuals have been diagnosed with ADH1 in the U.S. since October 2023, based on claims data.
The application is supported by results from CALIBRATE, a Phase 3 clinical trial in which encaleret met all pre-specified primary and key secondary efficacy endpoints. Results were presented at the European Congress of Endocrinology 2026 and the Endocrine Society 2026 annual meeting.
Encaleret is an orally administered small molecule designed to modulate the calcium sensing receptor. The drug has received Fast Track Designation from the FDA and Orphan Drug Designation in the U.S., European Union, and Japan.
BridgeBio stated it intends to submit a Marketing Authorization Application to the European Medicines Agency for encaleret in ADH1 in the second half of 2026.
The company is currently enrolling CALIBRATE-PEDS, a Phase 2/3 trial studying encaleret in pediatric ADH1. BridgeBio also plans to initiate RECLAIM-HP, a Phase 3 study of encaleret in chronic hypoparathyroidism, later this summer.
There are currently no approved therapies specifically indicated for ADH1.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。